WebApr 25, 2024 · Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2024 as follows: WebApr 14, 2024 · SAN DIEGO, April 14, 2024--Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced …
Evofem Biosciences (EVFM) Financial Statements: Income - Stock …
WebAug 4, 2024 · Evofem continues to expect net product sales in the range of $30 to $35 million for its 2024 fiscal year, representing 264% to 325% growth year-over-year. Gross … WebDescription. Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). saint ambrose catholic school houston texas
Evofem Biosciences Reports Fourth Quarter and Year-End …
Web6 minutes ago · SAN DIEGO , April 14, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. , (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2024.Reporting to Chief Executive Officer Saundra Pelletier … Web6 minutes ago · SAN DIEGO , April 14, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. , (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), … WebEvofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced it has implemented measures to lower its operating expenses, with the goal of reaching cash … thierry sauvageot